

# Conclusions

- Drug-Eluting technology performance in SFA is proving efficacious and beneficial (e.g., Ranger DCB FIM, Ranger DCB All Comers, Eluvia DES MAJESTIC studies)
- Critical Limb Ischaemia and Below the Knee interventions pose unique challenges that could be addressed by dedicated DCB and DES technologies
- Newer technologies coupled with multidisciplinary approaches are needed to achieve meaningful patient outcomes
- Going further in efforts to save limbs and patients' quality of remaining life is key

# Going further with Drug Eluting Technology in PAD: From SFA to Below the Knee Challenges

**Dierk Scheinert**

University Leipzig  
Medical Centre  
Leipzig, Germany

**Michael Lichtenberg**

Klinikum Arnsberg  
Arnsberg, Germany

**Marc Sapoval**

Hôpital Européen  
Georges Pompidou  
Paris, France

**Hans van Overhagen**

Haga Teaching Hospital  
Den Haag, the  
Netherlands

**Jihad Mustapha**

Advanced Cardiac & Vascular  
Amputation Prevention Centers  
Grand Rapids, MI USA

**Roberto Ferraresi**

Humanitas Gavazzeni  
Bergamo, Italy

**Live case from Leipzig**

University Hospital Leipzig  
Dep. Angiology - Live case center

Tuesday, January 30 15:00 – 16:30

Supported with an educational grant from Boston Scientific